18 0 2 0 2 B-lower_bound
years 3 8 3 8 I-lower_bound
or 9 11 9 11 O
older 12 17 12 17 O

At 0 2 18 20 O
least 3 8 21 26 O
one 9 12 27 30 B-lower_bound
site 13 17 31 35 O
of 18 20 36 38 O
measurable 21 31 39 49 O
disease 32 39 50 57 O
in 40 42 58 60 O
subjects 43 51 61 69 O
with 52 56 70 74 O
solid 57 62 75 80 B-cancer
tumors 63 69 81 87 I-cancer
and 70 73 88 91 O
NHL 74 77 92 95 B-cancer

Eastern 0 7 96 103 B-clinical_variable
Cooperative 8 19 104 115 I-clinical_variable
Oncology 20 28 116 124 I-clinical_variable
Group 29 34 125 130 I-clinical_variable
Performance 35 46 131 142 I-clinical_variable
Status 47 53 143 149 I-clinical_variable
( 54 55 150 151 I-clinical_variable
ECOG 55 59 151 155 I-clinical_variable
PS 60 62 156 158 I-clinical_variable
) 62 63 158 159 I-clinical_variable
of 64 66 160 162 O
0 67 68 163 164 B-lower_bound
or 69 71 165 167 O
1 72 73 168 169 B-upper_bound

Females 0 7 170 177 B-gender
and 8 11 178 181 O
males 12 17 182 187 O
must 18 22 188 192 O
agree 23 28 193 198 B-contraception_consent
to 29 31 199 201 I-contraception_consent
contraceptive 32 45 202 215 I-contraception_consent
methods 46 53 216 223 I-contraception_consent
and 54 57 224 227 O
avoid 58 63 228 233 O
conceiving 64 74 234 244 O
throughout 75 85 245 255 O
the 86 89 256 259 O
study 90 95 260 265 O
, 95 96 265 266 O
and 97 100 267 270 O
for 101 104 271 274 O
up 105 107 275 277 O
to 108 110 278 280 O
8 111 112 281 282 B-upper_bound
weeks 113 118 283 288 I-upper_bound
following 119 128 289 298 O
the 129 132 299 302 O
last 133 137 303 307 O
dose 138 142 308 312 O
of 143 145 313 315 O
CC-90002 146 154 316 324 O

High 0 4 325 329 B-cancer
grade 5 10 330 335 I-cancer
lymphomas 11 20 336 345 I-cancer
( 21 22 346 347 O
Burkitts 22 30 347 355 B-cancer
or 31 33 356 358 O
lymphoblastic 34 47 359 372 B-cancer
) 47 48 372 373 O
, 48 49 373 374 O
plasma 50 56 375 381 B-cancer
cell 57 61 382 386 I-cancer
leukemia 62 70 387 395 I-cancer

High 0 4 396 400 O
grade 5 10 401 406 O
, 10 11 406 407 O
rapidly 12 19 408 415 O
proliferative 20 33 416 429 O
solid 34 39 430 435 B-cancer
tumors 40 46 436 442 I-cancer
( 47 48 443 444 O
eg 48 50 444 446 O
, 50 51 446 447 O
small 52 57 448 453 B-cancer
cell 58 62 454 458 I-cancer
lung 63 67 459 463 I-cancer
cancer 68 74 464 470 I-cancer
, 74 75 470 471 O
germ 76 80 472 476 B-cancer
cell 81 85 477 481 I-cancer
tumors 86 92 482 488 I-cancer
, 92 93 488 489 O
neuroblastoma 94 107 490 503 B-cancer
) 107 108 503 504 O
with 109 113 505 509 O
extensive 114 123 510 519 O
tumor 124 129 520 525 O
burden 130 136 526 532 O

History 0 7 533 540 O
of 8 10 541 543 O
autoimmune 11 21 544 554 B-chronic_disease
hemolytic 22 31 555 564 I-chronic_disease
anemia 32 38 565 571 I-chronic_disease
or 39 41 572 574 O
autoimmune 42 52 575 585 B-chronic_disease
thrombocytopenia 53 69 586 602 I-chronic_disease

History 0 7 603 610 O
of 8 10 611 613 O
concurrent 11 21 614 624 O
second 22 28 625 631 O
cancers 29 36 632 639 B-cancer
requiring 37 46 640 649 O
active 47 53 650 656 O
, 53 54 656 657 O
ongoing 55 62 658 665 O
systemic 63 71 666 674 B-treatment
treatment 72 81 675 684 I-treatment

Impaired 0 8 685 693 O
cardiac 9 16 694 701 O
function 17 25 702 710 O
or 26 28 711 713 O
clinically 29 39 714 724 O
significant 40 51 725 736 O
cardiac 52 59 737 744 B-chronic_disease
disease 60 67 745 752 I-chronic_disease

Known 0 5 753 758 O
HIV 6 9 759 762 B-chronic_disease
infection 10 19 763 772 I-chronic_disease

Known 0 5 773 778 O
chronic 6 13 779 786 B-chronic_disease
, 13 14 786 787 I-chronic_disease
active 15 21 788 794 I-chronic_disease
hepatitis 22 31 795 804 I-chronic_disease
B 32 33 805 806 I-chronic_disease
or 34 36 807 809 I-chronic_disease
C 37 38 810 811 I-chronic_disease
( 39 40 812 813 I-chronic_disease
HBV 40 43 813 816 I-chronic_disease
/ 43 44 816 817 I-chronic_disease
HCV 44 47 817 820 I-chronic_disease
) 47 48 820 821 I-chronic_disease
infection 49 58 822 831 I-chronic_disease

Major 0 5 832 837 B-treatment
surgery 6 13 838 845 I-treatment
≤ 14 15 846 847 O
2 16 17 848 849 B-upper_bound
weeks 18 23 850 855 I-upper_bound
prior 24 29 856 861 I-upper_bound
to 30 32 862 864 O
starting 33 41 865 873 O
CC-90002 42 50 874 882 O

Men 0 3 883 886 B-gender

Multiple 0 8 887 895 B-cancer
Myeloma 9 16 896 903 I-cancer
( 17 18 904 905 I-cancer
MM 18 20 905 907 I-cancer
) 20 21 907 908 I-cancer
or 22 24 909 911 O
non 25 28 912 915 B-cancer
- 28 29 915 916 I-cancer
Hodgkin 29 36 916 923 I-cancer
's 36 38 923 925 I-cancer
lymphoma 39 47 926 934 I-cancer
( 48 49 935 936 I-cancer
NHL 49 52 936 939 I-cancer
) 52 53 939 940 I-cancer
in 54 56 941 943 O
Part 57 61 944 948 O
A. 62 64 949 951 O
In 65 67 952 954 O
Part 68 72 955 959 O
B 73 74 960 961 O
, 74 75 961 962 O
relapsed 76 84 963 971 O
and/or 85 91 972 978 O
refractory 92 102 979 989 O
CD20 103 107 990 994 O
- 107 108 994 995 O
positive 108 116 995 1003 O
NHL 117 120 1004 1007 O
subjects 121 129 1008 1016 O
only 130 134 1017 1021 O

Ongoing 0 7 1022 1029 O
treatment 8 17 1030 1039 B-treatment
with 18 22 1040 1044 O
chronic 23 30 1045 1052 B-chronic_disease
, 30 31 1052 1053 O
therapeutic 32 43 1054 1065 O
dosing 44 50 1066 1072 O
of 51 53 1073 1075 O
anti 54 58 1076 1080 B-treatment
- 58 59 1080 1081 I-treatment
coagulants 59 69 1081 1091 I-treatment

Pregnant 0 8 1092 1100 B-pregnancy

Prior 0 5 1101 1106 O
Red 6 9 1107 1110 B-clinical_variable
blood 10 15 1111 1116 I-clinical_variable
cell 16 20 1117 1121 I-clinical_variable
( 21 22 1122 1123 I-clinical_variable
RBC 22 25 1123 1126 I-clinical_variable
) 25 26 1126 1127 I-clinical_variable
transfusion 27 38 1128 1139 I-clinical_variable
< 39 40 1140 1141 O
3 41 42 1142 1143 B-upper_bound
months 43 49 1144 1150 I-upper_bound
prior 50 55 1151 1156 I-upper_bound
to 56 58 1157 1159 O
starting 59 67 1160 1168 O
CC-90002 68 76 1169 1177 B-treatment
( 77 78 1178 1179 I-treatment
Part 78 82 1179 1183 I-treatment
A 83 84 1184 1185 I-treatment
only 85 89 1186 1190 I-treatment
) 89 90 1190 1191 I-treatment

Prior 0 5 1192 1197 O
allogeneic 6 16 1198 1208 B-treatment
stem 17 21 1209 1213 I-treatment
cell 22 26 1214 1218 I-treatment
transplant 27 37 1219 1229 I-treatment
with 38 42 1230 1234 O
either 43 49 1235 1241 O
standard 50 58 1242 1250 O
or 59 61 1251 1253 O
reduced 62 69 1254 1261 O
intensity 70 79 1262 1271 O
conditioning 80 92 1272 1284 O
≤ 93 94 1285 1286 O
6 95 96 1287 1288 B-upper_bound
months 97 103 1289 1295 I-upper_bound
prior 104 109 1296 1301 I-upper_bound
to 110 112 1302 1304 O
starting 113 121 1305 1313 O
CC-90002 122 130 1314 1322 O

Prior 0 5 1323 1328 B-treatment
autologous 6 16 1329 1339 I-treatment
stem 17 21 1340 1344 I-treatment
cell 22 26 1345 1349 I-treatment
transplant 27 37 1350 1360 I-treatment
≤ 38 39 1361 1362 O
3 40 41 1363 1364 B-upper_bound
months 42 48 1365 1371 I-upper_bound
prior 49 54 1372 1377 I-upper_bound
to 55 57 1378 1380 O
starting 58 66 1381 1389 O
CC-90002 67 75 1390 1398 B-treatment

Prior 0 5 1399 1404 O
systemic 6 14 1405 1413 O
cancer 15 21 1414 1420 B-cancer
- 21 22 1420 1421 O
directed 22 30 1421 1429 O
treatments 31 41 1430 1440 O
or 42 44 1441 1443 O
investigational 45 60 1444 1459 O
modalities 61 71 1460 1470 O
≤ 72 73 1471 1472 O
5 74 75 1473 1474 B-upper_bound
half 76 80 1475 1479 O
lives 81 86 1480 1485 O
or 87 89 1486 1488 O
4 90 91 1489 1490 B-upper_bound
weeks 92 97 1491 1496 I-upper_bound
prior 98 103 1497 1502 I-upper_bound
to 104 106 1503 1505 O
starting 107 115 1506 1514 O
CC-90002 116 124 1515 1523 O
, 124 125 1523 1524 O
whichever 126 135 1525 1534 O
is 136 138 1535 1537 O
shorter 139 146 1538 1545 O

nursing 0 7 1546 1553 O
females 8 15 1554 1561 B-gender

relapsed 0 8 1562 1570 O
or 9 11 1571 1573 O
refractory 12 22 1574 1584 O
solid 23 28 1585 1590 B-cancer
tumors 29 35 1591 1597 I-cancer

women 0 5 1598 1603 B-gender

